M&A

News

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.

News

Sanofi in talks to sell stake in consumer health spinout

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.

News

Lawmaker asks FTC to probe Novo/Catalent deal

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operate

R&D

Merger and acquisition visual concept with buildings and jigsaw

Closed and Collaborative: Mergers, acquisitions, and partner...

As we head further into H2, a final look back to the summer’s industry mergers and acquisiti

R&D

Closed and Collaborative: Mergers, acquisitions, and partner...

Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry

News

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Sanofi in talks to sell stake in consumer health spinout

Lawmaker asks FTC to probe Novo/Catalent deal

Closed and Collaborative: Mergers, acquisitions, and partner...

Closed and Collaborative: Mergers, acquisitions, and partner...

Organon makes dermatology play with $1.2bn Dermavant buyout

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks